Tectonic Therapeutic

TECX

Market cap $356M

Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) patients. TECX is targeting CpcPH patients with PVR >3 in the ongoing phase 2 APEX study of PH-HFpEF, with topline data expected in 2026 and expansion into PH-ILD planned then also. TECX holds $268.4 million in cash, sufficient to fund operations into Q4 2028 and support multiple clinical milestones, including several catalysts.

Tectonic Therapeutic, Inc. ( TECX ) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients October 29, 2025 4:30 PM EDT Company Participants Alise Reicin - President, CEO, Secretary & Director Marcella Ruddy - Chief Medical Officer Conference Call Participants Frances Dovell - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Alexander Nackenoff - Truist Securities, Inc., Research Division Martin Auster - Raymond James & Associates, Inc., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Presentation Operator Good day, and welcome to the TX45 Phase Ib Part B PH-HFrEF data conference call. [Operator Instructions] As a reminder, this call may be recorded.

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose of TX45 was well tolerated in this patient population and resulted in meaningful improvements in both left heart function and pulmonary hemodynamics.

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025.

Tectonic Therapeutic (TECX -5.35%), a biotechnology company advancing a new generation of biologic medicines for hard-to-treat diseases, reported its second quarter 2025 results on August 7, 2025. The headline news was a net loss (GAAP) of $20.0 million in Q2 2025, with a loss per share of $(1.07) (GAAP), wider than analysts' expectations of $(0.98) (GAAP).

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025.

WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia. The results include the full cohort of 19 patients in Part A of the Phase 1b trial of TX45, Tectonic's lead asset and a long-acting relaxin therapy. Interim data for 16 patients in the Phase 1b trial was previously reported in a press release on January 30, 2025.

The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent business highlights.

We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026.